Racial Disparity in Response to Prostate Cancer Systemic Therapies.

Journal Article (Journal Article;Review)

PURPOSE OF REVIEW: In this review, we aim to describe racial differences in response to treatment for metastatic castration-resistant prostate cancer (mCRPC). RECENT FINDINGS: Recent data suggests that, despite higher risk features, African Americans may respond better than Caucasians to systemic therapies for advanced prostate cancer. This improved response is not limited to one class of drugs but can be seen with androgen-pathway directed therapies, chemotherapy, bone-targeted therapy, and immunotherapy. The mechanisms for this are being further explored. African Americans may respond better to mCRPC treatments but validation in prospective clinical trials is needed.

Full Text

Duke Authors

Cited Authors

  • Bitting, RL; Goodman, M; George, DJ

Published Date

  • July 23, 2020

Published In

Volume / Issue

  • 22 / 9

Start / End Page

  • 96 -

PubMed ID

  • 32700096

Electronic International Standard Serial Number (EISSN)

  • 1534-6269

Digital Object Identifier (DOI)

  • 10.1007/s11912-020-00966-z

Language

  • eng

Conference Location

  • United States